BioInformant

Your Global Leader in Stem Cell Market Research

Home » interview » Page 2

Basilard Biotech to Transform the Engineering of Cell-based Therapies Using Their Novel Nanomechanical Gene Delivery Technology

By Leave a Comment

Basilard Biotech LogoBasilard Biotech is a Southern-California-based company poised to lead a revolution in the engineering of cell based therapies in Cell and Gene Therapy (CGT). In 2019, the company launched a disruptive gene delivery technology platform called SoloPore™. This novel approach to nanomechanical gene delivery has the potential to disrupt the current limitations of current viral and non-viral gene delivery—a breakthrough that could facilitate better scalability and more  cost-effective production of cell and gene therapies.

In this interview with Brynley Lee, CEO of Basilard, we learn about the formation of Basilard Biotech, explore the company’s novel SoloPore™ technology, dive into the company’s funding strategy, and explore its future goals. Enjoy! [Read more…]

Disrupting the Cell Therapy Market: Nucleus Biologics Brings Transparency, Customization & Control

By Leave a Comment

In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration.

The pace never slows when your mission is to enable lifesaving science! [Read more…]

How Celularity is Leading the Next Evolution in Cellular Medicine

By 2 Comments

Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. Using proprietary technology in combination with its IMPACT™ platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative and highly scalable off-the-shelf treatments for patients with cancer, inflammatory and age-related diseases.

Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity is uniquely positioned to harness the potential of most biocreative event on earth: human birth. [Read more…]

Cord Blood Market Consolidation in Latin America

By Leave a Comment

In this interview with James Alexis Mendez, we discuss the market strategy of CryoHoldco, a stem cell bank holding company that is the market leader in Latin America and one of the ten largest cord blood banks in the world. James Alexis Mendez currently serves as the CFO and Board member of CryoHoldco.

Approaching 200,000 stem cell units in storage, CryoHoldco is more than 5X larger than any other stem cell bank in Latin America. CryoHoldco owns the cord blood market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America.

In this interview, we discuss the current and future state of cord blood banking within Latin America, Cryoholdco’s role within this evolving marketplace, and future directions for the company.

Prior to initiating the consolidation strategy of CryoHoldco with ACON Investments, Alexis was a Director of TCP Latam, a private equity and restructuring fund in Brazil.  Prior to TCP Latam, he was a senior associate at Long Point Capital, a leveraged-buyout private equity fund in New York, where Alexis was responsible for equity investments in excess of USD $100 million in several private companies.

[Read more…]

Minerva Biotechnologies, Interview with CEO Dr. Cynthia Bamdad

By 1 Comment

Minerva Biotechnologies is a regenerative medicine company specializing in stem cell therapeutics that is developing cancer immunotherapies to target 75% of solid tumors and to prevent cancer metastasis. I had the honor of interviewing Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies.

In this interview, we discuss Minerva’s technology platform, product portfolio, IP strategy, and strategic goals. We also explore the significance of the company’s AlphaSTEM™ Culture System that is a simple method for inducing the naïve state in human stem cells. Enjoy. [Read more…]

BioInformant's World-Class Clients